Clinical Hours
| Day | Availability |
|---|---|
| Wednesday | Every week |
| Saturday | 1st and 3rd Saturday of each month |
Bio
Dr. Tan Sui Keat treats all hematology conditions and blood cancers with a special interest in Leukemia, Lymphoma, Multiple Myeloma, Bone Marrow Transplantation and Cellular Therapy.
Dr. Tan completed his Doctor of Medicine, Universiti Kebangsaan Malaysia (UKM) in 2008, and in 2015, achieved Membership of the Royal Colleges of Physicians of the United Kingdom, MRCP(UK) qualification. Driven by his interest in hematology, he further pursued a Fellowship in Bone Marrow and Stem Cell Transplantation at St Vincent Hospital in Sydney, Australia, in 2020.
With over 17 years of medical experience and 7 years specialising in Hematology, Dr. Tan is a highly accomplished hematologist. He has been invited to present at several prestigious local and regional medical conferences. To date, he has delivered more than 15 oral and poster presentations, including a notable oral presentation on ‘Genotype and Clinical Characterization of HbH Disease in Malaysian Patients’ at the British Society of Hematology Annual Congress in 2022, the Congress of the Asia Pacific Society on Thrombosis and Hemostasis and the 28th Annual Meeting of the Asia-Pacific Blood and Marrow Transplantation Group in 2023.
He has contributed significantly to the medical community, with key publications such as the first-authored paper, ‘Genotype and Clinical Characterisation of HbH Disease in Malaysian Patients’ published in the British Journal of Hematology (April 2022), and ‘Risk Factors and Outcomes of COVID-19 Infection in Hematological Patients: A Multicenter Retrospective Analysis in Malaysia’ published in Blood (2022) 140 (Supplement 1): 13232-13233.
Dr. Tan is deeply passionate about research and has served as both Principal Investigator and Co-Investigator for over 10 clinical trials focused on blood disorders and cancers. He is also a member of the Cellular Therapy Advisory Committee of Malaysian Society of Hematology as well as a member of the Expert Committee Health Technology Assessment for CART Cell for Relapsed Refractory Acute Lymphoblastic Leukemia by Ministry of Health in 2024.
Dr. Tan’s commitment to patient-centric care has earned him the Excellent Service Award from the Penang State Health Department twice, in 2013 and 2023, reflecting his dedication to providing personalised care and evidence-based treatments.
Dr. Tan is fluent in English, Bahasa Melayu, Mandarin, Hokkien, Cantonese, ensuring patients and their families feel comfortable communicating in their preferred language.
Dr. Tan is available for patient consultations every Wednesday as well as every first and third Saturday of the month at Icon Oncology.
Clinical Trials
- COMMODORE (2018) – A Randomised, Open Label Phase 3 study assessing the safety and tolerability of the oral FLT3 inhibitor Gliteritinib versus salvage chemotherapy in relapsed or refractory AML – Co-investigator
- EXPLORER 4 (2018) – A Randomised, Open Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylatic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors – Co-investigator
- BELIEVE (2018) – A Phase 3, double blind, randomized, placebo-controlled, multicentre study to determine the efficacy and safety of luspatercept plus Best Supportive Care versus placebo plus BSC in adults who require regular red blood cell transfusion due to Beta Thalassemia – Co-investigator
- VIALE –T (2020) – A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitdine after ASCT in subjects with AML – Co-investigator
- VEDO-3035 (2020) – A Randomized, Double Blind, Placebo – controlled, Multicenter Study to evaluate the efficacy and safety of Vedolizumab in the prophylaxis of Intestinal acute GVHD in subjects undergoing alloSCT – Co-investigator
- ASSURE (2020) – A Phase II dose escalation study of cyclophosphamide in hematopoietic stem cell transplantation in severe systemic sclerosis patient unfit for standard dose of cyclophosphamide – Co-investigator
- IMARA (2021) — A Phase 2, Randomized, Double Blind, Placebo controlled study to evaluate the safety, tolerability, PK and PD of IMR-687 in adult subjects with B-Thalassemia – Co-investigator
- BO42162 (2021) – A Phase III, Randomized, Open Label Active Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab versus Eculizumab in adult and adolescent patients with PNH not previously treated with complement inhibitors – Co-investigator
- CABL001J12301(2022) – A Phase III, multi-center, open-label, randomized study of oral asciminib versus investigator selected TKI in patients with newly diagnosed CML in CP – Co-investigator
- CABL001A2302(2022) – A Phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with CML in CP previously treated with 2 or more TKI – Co-investigator
- MANIFEST II (2023) – A Phase 3, Randomized, Double – Blind, Active Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment Naïve MF Patients – Principal Investigator
- MajesTEC-9 (2023) – A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 prior lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide – Principal Investigator
- BELLWAVE (2024) – A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Ibrutinib or Acalabrutinib) in Participants with Untreated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma – Principal Investigator
- GOLSEEK (2025) – A phase 3, Multicenter, Randomized, Double Blind, Placebo- controlled Study. Comparing the Efficacy and Safety of Golcadomide plus R-CHOP Chemotherapy vs Placebo plus RCHOP Chemotherapy in Participants with Previously Untreated High – risk Large B cell Lymphoma – Principal Investigator